EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Managing Rebound Bone Loss After Denosumab Discontinuation: Mechanisms, Risk Stratification, and Sequential Therapy

Ahmad, Yuting Liao, Mei Yu, Jiamei Xu, Yankui Zhai, Qixian Xiao, Guocai Wang, Zuocheng Qiu, Yanzhi Liu iD

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s640547 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Ahmad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong, 524045, People's Republic of China. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Bone Resorption, Osteoporosis. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBone Density Conservation AgentsBone ResorptionOsteoporosisHumansBone DensityRisk AssessmentBridge Therapy

Stichwörter der Autor:innen

bone turnover markersdenosumab discontinuationosteoporosisrebound bone losssequential therapyserum CTXvertebral fractures

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong, 524045, People's Republic of China.
  • School of Pharmacy, Jinan University, Guangzhou, 511443, People's Republic of China.
  • Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Infectious Diseases, Zhanjiang Central Hospital, Guangdong Medical University (Central People's Hospital of Zhanjiang), Zhanjiang, Guang…
  • School of Pharmacy, Guangdong Medical University, Zhanjiang, 524023, People's Republic of China.
  • Marine Medical Research Institute of Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, Guangdong, 524023, People's Republic of China.
  • Orthopedics Department, Zhanjiang Central Hospital, Guangdong Medical University (Central People's Hospital of Zhanjiang), Zhanjiang, Guangdong, 524045, People's Republic of China.

ORCID-Profile: Yanzhi Liu

Zitieren

APA

Ahmad, Liao, Y., Yu, M., Xu, J., Zhai, Y., Xiao, Q., Wang, G., Qiu, Z., & Liu, Y. (2026). Managing Rebound Bone Loss After Denosumab Discontinuation: Mechanisms, Risk Stratification, and Sequential Therapy. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s640547

Vancouver

Ahmad, Liao Y, Yu M, Xu J, Zhai Y, Xiao Q, et al. Managing Rebound Bone Loss After Denosumab Discontinuation: Mechanisms, Risk Stratification, and Sequential Therapy. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s640547

BibTeX
@article{Ahmad2026,
  author = {Ahmad and Liao, Yuting and Yu, Mei and Xu, Jiamei and Zhai, Yankui and Xiao, Qixian and Wang, Guocai and Qiu, Zuocheng and Liu, Yanzhi},
  title = {Managing Rebound Bone Loss After Denosumab Discontinuation: Mechanisms, Risk Stratification, and Sequential Therapy},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s640547}
}
Kostenlos starten →